KATNAL1: A Potential Drug Target and Biomarker for Neurological Disorders

Target Name: KATNAL1

NCBI ID: G84056

KATNAL1

KATNAL1: A Potential Drug Target and Biomarker for Neurological Disorders

KATNAL1, also known as katanin p60 subunit A like 1, is a protein that is expressed in various tissues throughout the body. It is a member of the katanin gene family, which is characterized by the presence of a characteristic domain called the p60 subunit. The p60 subunit is a transmembrane protein that is involved in various cellular processes, including intracellular signaling, cell adhesion, and neurotransmission.

Recent studies have identified KATNAL1 as a potential drug target or biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. This has led to increased interest in the research of KATNAL1 and its potential applications in drug development.

KATNAL1 as a drug target

KATNAL1 has been identified as a potential drug target due to its involvement in various cellular processes that are implicated in the development and progression of neurological and psychiatric disorders.

First, KATNAL1 has been shown to be involved in the regulation of intracellular signaling pathways, including the TGF-β pathway. This pathway is involved in the development and maintenance of neural stem cells, and is thought to play a role in the development of neurodegenerative diseases.

Second, KATNAL1 has been shown to be involved in the regulation of cell adhesion. This is important for the proper functioning of neural stem cells and for the development of neural circuits.

Third, KATNAL1 has been shown to be involved in the regulation of neurotransmission. This is important for the proper functioning of neural circuits and for the development of neurodegenerative diseases.

KATNAL1 as a biomarker

In addition to its potential as a drug target, KATNAL1 has also been identified as a potential biomarker for various neurological and psychiatric disorders.

Studies have shown that KATNAL1 levels are often decreased in individuals with Alzheimer's disease and other forms of dementia. This suggests that KATNAL1 may be a useful biomarker for these disorders.

Similarly, KATNAL1 levels have been shown to be decreased in individuals with depression and other psychiatric disorders. This suggests that KATNAL1 may be a useful biomarker for these disorders as well.

KATNAL1 is also a potential biomarker for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Studies have shown that KATNAL1 levels are often decreased in individuals with these disorders, and that levels may be correlated with the severity of the disease.

Conclusion

In conclusion, KATNAL1 is a protein that is expressed in various tissues throughout the body and has been shown to be involved in various cellular processes that are important for the development and progression of neurological and psychiatric disorders. The potential drug target and biomarker properties of KATNAL1 have generated increased interest in its research and potential applications in drug development. Further studies are needed to fully understand the role of KATNAL1 in neurological and psychiatric disorders.

Protein Name: Katanin Catalytic Subunit A1 Like 1

Functions: Regulates microtubule dynamics in Sertoli cells, a process that is essential for spermiogenesis and male fertility. Severs microtubules in an ATP-dependent manner, promoting rapid reorganization of cellular microtubule arrays (By similarity). Has microtubule-severing activity in vitro (PubMed:26929214)

The "KATNAL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KATNAL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets